Antidiabetic effect of galantamine: Novel effect for a known centrally acting drug

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Ali, Mennatallah A ^a   El Abhar, Hanan S ^b   Kamel, Maher A ^c   Attia, Ahmed S ^b  

^a Pharos University in Alexandria   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA CATENIN; CASPASE 3; CYTOCHROME C; FRUCTOSAMINE; GALANTAMINE; GLUCOSE; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; MALONALDEHYDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; VILDAGLIPTIN; WNT PROTEIN; ADIPOCYTOKINE; ANTIDIABETIC AGENT; AUTACOID; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; GLUCOSE BLOOD LEVEL; LIPID;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; CELL FUNCTION; CHEMICAL PARAMETERS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; INSULIN BLOOD LEVEL; LIPID ANALYSIS; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; RAT; SIGNAL TRANSDUCTION; TOTAL ANTIOXIDANT CAPACITY; ANIMAL; BLOOD; BODY WEIGHT; BRAIN; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODEL; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; LIPID METABOLISM; LIVER; METABOLISM; SKELETAL MUSCLE; WNT SIGNALING PATHWAY;

ADIPOKINES; ANIMALS; APOPTOSIS; BIOMARKERS; BLOOD GLUCOSE; BODY WEIGHT; BRAIN; CASPASE 3; CHOLINESTERASE INHIBITORS; CYTOCHROMES C; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GALANTAMINE; GLUCOSE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; LIPID METABOLISM; LIPIDS; LIVER; MUSCLE, SKELETAL; RATS; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84943156259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134648     Document Type: Article

References (80)

1. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol. 2011;71(3):365-76. doi: 10.1111/j.1365-2125.2010.03830.x PMID: 21284695
2. Van Raalte DH, Diamant M. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? Diabetes Res Clin Pract. 2011;93:S37-46. doi: 10.1016/S0168-8227 (11) 70012-2 PMID: 21864750
3. Schmatz R, Mazzanti CM, Spanevello R, Stefanello N, Gutierres J, Corrêa M, et al. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2009;610(1-3):42-8. doi: 10.1016/j.ejphar.2009.03.032 PMID: 19303406
4. Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun. 2009;23(1):41-5. doi: 10.1016/j.bbi.2008.06.011 PMID: 18639629
5. Satapathy SK, Ochani M, Dancho M, Hudson LK, Rosas-Ballina M, Valdes-Ferrer SI, et al. Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Mol Med. 2011;17(7-8):599-606. doi: 10.2119/molmed.2011.00083 PMID: 21738953
6. Qi W, Yang C, Dai Z, Che D, Feng J, Mao Y, et al. High levels of pigment epithelium-derived factor in diabetes impair wound healing through suppression of wnt signaling. Diabetes. 2015;64(4):1407-19. doi: 10.2337/db14-1111 PMID: 25368097
7. Okada M, Imai T, Yaegaki K, Ishkitiev N, Tanaka T. Regeneration of insulin-producing pancreatic cells using a volatile bioactive compound and human teeth. J Breath Res. 2014;8(4):046004. doi: 10.1088/1752-7155/8/4/046004 PMID: 25358383
8. Ip W, Chiang Y, Jin T. The involvement of the wnt signaling pathway and TCF7L2 in diabetes mellitus: The current understanding, dispute, and perspective. Cell Biosci. 2012;2(1):28. doi: 10.1186/2045-3701-2-28 PMID: 22892353
9. Romero A, Egea J, García AG, López MG. Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. J Pineal Res. 2010;49(2):141-8. doi: 10.1111/j.1600-079X.2010.00778.x PMID: 20536682
10. Traykova M, Trakov T, Hadjimitova V, Krikorian K, Bojadgieva N. Antioxidant properties of galantamine hydrobromide. Z Naturforsch C. 2003;58(5-6):361-5. PMID: 12872930
11. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, et al. alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem. 2001;276(17):13541-6. PMID: 11278378
12. Wills S, inventor. Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors. US; 2009/0081314 A1, 2009.
13. Portha B, Movassat J, Cuzin-Tourrel C, Bailbe D, Giroix MH, Serradas P, et al. Neonatally Streptozotocin-Induced (n-STZ) Diabetic Rats: A Family of Type 2 Diabetes Models. In: Shafrir E, editor. Animal Models of Diabetes, Frontiers in Research. 2nd ed. Amsterdam: Harwood Academic, CRC Press, Taylor & Francis Group; 2007. pp. 223-50.
14. Garber JC, Barbee RW, Bielitzki JT, Clayton LA, Hendriksen CF, Donovan JC, et al. Guide for the care and use of laboratory animals. 8th ed. Washington, DC: The National Academic Press; 2010. doi: 10. 1258/la.2010.010031 PMID: 21123303
15. Zhao CS, Puurunen K, Schallert T, Sivenius J, Jolkkonen J. Effect of cholinergic medication, before and after focal photothrombotic ischemic cortical injury, on histological and functional outcome in aged and young adult rats. Behav Brain Res. 2005;156(1):85-94. PMID: 15474653
16. Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, et al. Galantamine-induced amyloid-α clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem. 2010;285(51):40180-91. doi: 10.1074/jbc. M110.142356 PMID: 20947502
17. Monbaliu J, Verhaeghe T, Willems B, Bode W, Lavrijsen K, Meuldermans W. Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species. Arzneimittelforschung. 2003;53(7):486-95. PMID: 12918214
18. Akarte AS, Srinivasan BP, Gandhi S. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates α-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. J Diabetes Complications. 2012;26(4):266-74. doi: 10.1016/j. jdiacomp. 2012.03.013 PMID: 22626875
19. Tilethe S, Chourasiya PK, Dhakad RS, Kumar D. Potential of rutin and vildagliptin combination against alloxan induced diabetic nephropathy in mice. Res J Pharmaceutical Sci. 2013;2(9):1-7.
20. Psyrogiannis A, Kyriazopoulou V, Symeonidis A, Leotsinidis M, Vagenakis AG. Relative iron "overload" in offspring of patients with type 2 diabetes mellitus: a new component in the conundrum of insulin resistance syndrome? Hormones (Athens). 2003;2:161-8.
21. Lopes-Virella MF, Stone PG, Colwell JA. Serum high density lipoprotein in diabetic patients. Diabetologia. 1977;13(4):285-91. PMID: 199515
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. PMID: 4337382
23. Akarte A, Srinivasan B, Gandhi S. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates α-cell proliferation resulting in improved glucose homeostasis in diabetic rats. Biochem Pharmacol. 2012;83(2):241-52. doi: 10.1016/j.bcp. 2011.10.003 PMID: 22015634
24. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-7. PMID: 13671378
25. Muthusamy VR, Kannan S, Sadhaasivam K, Gounder SS, Davidson CJ, Boeheme C, et al. Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardium. Free Radic Biol Med. 2012;52(2):366-76. doi: 10.1016/j.freeradbiomed.2011.10.440 PMID: 22051043
26. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86:271-8. PMID: 655387
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-75. PMID: 14907713
28. Smith JA, Kohn TA, Chetty AK, Ojuka EO. CaMK activation during exercise is required for histone hyperacetylation and MEF2A binding at the MEF2 site on the Glut4 gene. Am J Physiol Endocrinol Metab. 2008;295(3):E698-704. doi: 10.1152/ajpendo.00747.2007 PMID: 18647882
29. Kuhad A, Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol. 2007;576(1-3):34-42. PMID: 17822693
30. Masha'our RS, Heinrich R, Garzozi HJ, Perlman I. Acetylcholinesterase (AChE) is an important link in the apoptotic pathway induced by hyperglycemia in Y79 retinoblastoma cell line. Front Mol Neurosci. 2012;5:69. doi: 10.3389/fnmol.2012.00069 PMID: 22685426
31. De Oliveira AC, Andreotti S, Farias Tda S, Torres-Leal FL, De Proenca AR, Campana AB, et al. Metabolic disorders and adipose tissue insulin responsiveness in neonatally STZ-induced diabetic rats are improved by long-term melatonin treatment. Endocrinology. 2012;153(5):2178-88. doi: 10.1210/en. 2011-1675 PMID: 22374967
32. Allam AR, Sridhar GR, Thota H, Babu CS, Prasad AS, Divakar C. Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection? Lipids Health Dis. 2006;5(1):28.
33. Sajja RK, Prasad S, Cucullo L. Impact of altered glycaemia on blood-brain barrier endothelium: an in vitro study using the hCMEC/D3 cell line. Fluids Barriers CNS. 2014;11(1):8. doi: 10.1186/2045-8118-11-8 PMID: 24708805
34. Chistyakova OV, Bondareva VM, Shipilov VN, Sukhov IB, Shpakov AO. A positive effect of intranasal insulin on spatial memory in rats with neonatal diabetes mellitus. Endocrinology Studies. 2011;1(2):e16.
35. Val-Laillet D, Biraben A, Randuineau G, Malbert CH. Chronic vagus nerve stimulation decreased weight gain, food consumption and sweet craving in adult obese minipigs. Appetite. 2010;55(2):245-52. doi: 10.1016/j.appet.2010.06.008 PMID: 20600417
36. Jo YH, Wiedl D, Role LW. Cholinergic modulation of appetite-related synapses in mouse lateral hypothalamic slice. J Neurosci. 2005;25(48):11133-44. PMID: 16319313
37. Marrero MB, Lucas R, Salet C, Hauser TA, Mazurov A, Lippiello PM, et al. An alpha7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J Pharmacol Exp Ther. 2010;332(1):173-80. doi: 10.1124/jpet.109.154633 PMID: 19786623
38. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Jama. 2007;298(2):194-206. PMID: 17622601
39. Richter WO, Geiss HC, Aleksic S, Schwandt P. Cardiac autonomic nerve function and insulin sensitivity in obese subjects. Int J Obes Relat Metab Disord. 1996;20(10):966-9. PMID: 8910104
40. Oida E, Kannagi T, Moritani T, Yamori Y. Diabetic alteration of cardiac vago-sympathetic modulation assessed with tone-entropy analysis. Acta Physiol Scand. 1999;165(2):129-34. PMID: 10090323
41. Das UN. Vagus nerve stimulation as a strategy to prevent and manage metabolic syndrome. Med Hypotheses. 2011;76(3):429-33. doi: 10.1016/j.mehy.2010.11.013 PMID: 21144670
42. Balkan B, Kwasnik L, Miserendino R, Holst J, Li X. Inhibition of dipeptidyl peptidase IV with NVPDPP728 increases plasma GLP-1 (7.36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia. 1999;42(11):1324-31. PMID: 10550416
43. Drucker DJ. Incretin-based therapy and the quest for sustained improvements in α-cell health. Diabetes care. 2011;34(9):2133-5. doi: 10.2337/dc11-0986 PMID: 21868783
44. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther. 2005;315(2):688-95. PMID: 16027230
45. Hayes MR. Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. Physiol Behav. 2012;106(3):413-6. doi: 10.1016/j.physbeh.2012.02.017 PMID: 22366059
46. Bernsmeier C, Heim MH. Insulin resistance in chronic hepatitis C: mechanisms and clinical relevance. Swiss Med Wkly. 2009;139(47-48):678-84. doi: smw-12765 PMID: 20047129
47. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem. 2005;280(2):1457-64. PMID: 15525634
48. Jin T, Liu L. The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol Endocrinol. 2008;22(11):2383-92. doi: 10.1210/me.2008-0135 PMID: 18599616
49. Abiola M, Favier M, Christodoulou-Vafeiadou E, Pichard AL, Martelly I, Guillet-Deniau I. Activation of Wnt/beta-catenin signaling increases insulin sensitivity through a reciprocal regulation of Wnt10b and SREBP-1c in skeletal muscle cells. PLoS One. 2009;4(12):e8509. doi: 10.1371/journal.pone.0008509 PMID: 20041157
50. Yu Z, Jin T. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cell Signal. 2010;22(1):1-8. doi: 10.1016/j.cellsig.2009.09.032 PMID: 19772917
51. Martinez-Rodriguez R, Gil A. Nutrient-mediated modulation of incretin gene expression: a systematic review. Nutr Hosp. 2012;27(1):46-53. doi: 10.1590/S0212-16112012000100006 PMID: 22566303
52. Tavares FL, Seelaender MC. Hepatic denervation impairs the assembly and secretion of VLDL-TAG. Cell Biochem Funct. 2008;26(5):557-65. doi: 10.1002/cbf.1476 PMID: 18543355
53. Altuncu ME, Baspinar O, Keskin M. The use of short-term analysis of heart rate variability to assess autonomic function in obese children and its relationship with metabolic syndrome. Cardiol J. 2012;19(5):501-6. PMID: 23042314
54. Hajer GR, Van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart. 2008;29(24):2959-71.
55. Park HJ, Georgescu SP, Du C, Madias C, Aronovitz MJ, Welzig CM, et al. Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. J Clin Invest. 2008;118(1):259-71. PMID: 18060044
56. Pan CY, Wang XL. Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. Ther Clin Risk Manag. 2013;9:247-57. doi: 10.2147/TCRM. S30071 PMID: 23818788
57. Choe EY, Cho Y, Choi Y, Yun Y, Wang HJ, Kwon O, et al. The effect of DPP-4 inhibitors on metabolic parameters in patients with type 2 diabetes. Diabetes Metab J. 2014;38(3):211-9. doi: 10.4093/dmj. 2014.38.3.211 PMID: 25003075
58. Pi J, Zhang Q, Fu J, Woods CG, Hou Y, Corkey BE, et al. ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol Appl Pharmacol. 2010;244(1):77-83. doi: 10.1016/j.taap. 2009. 05.025 PMID: 19501608
59. Puddu A, Sanguineti R, Mach F, Dallegri F, Viviani GL, Montecucco F. Update on the protective molecular pathways improving pancreatic beta-cell dysfunction. Mediators Inflamm. 2013;750540:1-14.
60. Melo JB, Sousa C, Garcao P, Oliveira CR, Agostinho P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci. 2009;29(3):455-64. doi: 10.1111/j.1460-9568.2009.06612.x PMID: 19222556
61. Javed H, Khan A, Vaibhav K, Moshahid Khan M, Ahmad A, Ejaz Ahmad M, et al. Taurine ameliorates neurobehavioral, neurochemical and immunohistochemical changes in sporadic dementia of Alzheimer's type (SDAT) caused by intracerebroventricular streptozotocin in rats. Neurol Sci. 2013;34(12):2181-92. doi: 10.1007/s10072-013-1444-3 PMID: 23681104
62. Prakash A, Shur B, Kumar A. Naringin protects memory impairment and mitochondrial oxidative damage against aluminum-inducedneurotoxicity in rats. Int J Neurosci. 2013;123(9):636-45. doi: 10.3109/00207454.2013.785542 PMID: 23510099
63. Avila Dde L, Araujo GR, Silva M, Miranda PH, Diniz MF, Pedrosa ML, et al. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats. Arch Med Res. 2013;44(3):194-202. doi: 10.1016/j.arcmed.2013.03.004 PMID: 23523961
64. Abdelsalam RM, Safar MM. Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways. J Neurochem. 2015;133(5):700-7. doi: 10.1111/jnc.13087 PMID: 25752913
65. Tuzcu M, Baydas G. Effect of melatonin and vitamin E on diabetes-induced learning and memory impairment in rats. Eur J Pharmacol. 2006;537(1-3):106-10. PMID: 16626697
66. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(39):14205-18. doi: 10. 3748/wjg.v20.i39.14205 PMID: 25339807
67. Yang WM, Lee W. CTRP5 ameliorates palmitate-induced apoptosis and insulin resistance through activation of AMPK and fatty acid oxidation. Biochem Biophys Res Commun. 2014;452(3):715-21. doi: 10.1016/j.bbrc.2014.08.145 PMID: 25195818
68. Williams KH, Vieira De Ribeiro AJ, Prakoso E, Veillard A, Shackel NA, Brooks B, et al. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in nonalcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study. J Diabetes. 2014: doi: 10.1111/753-0407.12237
69. Kandhare AD, Raygude KS, Kumar VS, Rajmane AR, Visnagri A, Ghule AE, et al. Ameliorative effects quercetin against impaired motor nerve function, inflammatory mediators and apoptosis in neonatal streptozotocin-induced diabetic neuropathy in rats. Biomed Aging Pathol. 2012;2(4):173-86.
70. Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4(71):1-13.
71. Liu ZH, Ma YF, Wu JS, Gan JX, Xu SW, Jiang GY. Effect of cholinesterase inhibitor galanthamine on circulating tumor necrosis factor alpha in rats with lipopolysaccharide-induced peritonitis. Chin Med J (Engl). 2010;123(13):1727-30.
72. Sadis C, Detienne S, Vokaer B, Charbonnier LM, Lemaitre P, Spilleboudt C, et al. The cholinergic antiinflammatory pathway delays TLR-induced skin allograft rejection in mice: cholinergic pathway modulates alloreactivity. PLoS One. 2013;8(11):e79984. doi: 10.1371/journal.pone.0079984 PMID: 24278228
73. Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, et al. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res Bull. 2004;64(2):165-70. PMID: 15342104
74. Ponnappan U. Regulation of transcription factor NF kappa B in immune senescence. Front Biosci. 1998;3:d152-68. PMID: 9445466
75. Wang Y, Paszek P, Horton CA, Yue H, White MR, Kell DB, et al. A systematic study of the response of a NF-kappa B signalling pathway to TNF alpha stimulation. J Theor Biol. 2012;297:137-47. doi: 10. 1016/j.jtbi.2011.12.014 PMID: 22202812
76. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178(3):1748-58. PMID: 17237424
77. Garcia-Bailo B, El-Sohemy A, Haddad PS, Arora P, Ben Zaied F, Karmali M, et al. Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress. Biologics. 2011;5:7-19. doi: 10.2147/BTT. S14417 PMID: 21383912
78. El-Abhar HS, Schaalan MF. Topiramate-induced modulation of hepatic molecular mechanisms: an aspect for its anti-insulin resistant effect. PloS One. 2012;7(5):e37757. doi: 10.1371/journal.pone. 0037757 PMID: 22649556
79. Takeshita Y, Takamura T, Kita Y, Otoda T, Kato K, Wakakuri H, et al. Establishment of Rationale for Antiaging Diabetic Medicine (ERA-DM) Study Chapter 2 Group. Vildagliptin vs liraglutide as a secondline therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study. J Diabetes Investig. 2015;6:192-200. doi: 10.1111/jdi.12269 PMID: 25802727
80. Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A, et al. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metabolism. 2014;63:957-67. doi: 10.1016/j.metabol.2014.04.008 PMID: 24874591